FMP
NYSE
4.49 USD
0.29 (6.46%)
Dr. Ameet Mallik M.B.A., M.S.
Healthcare
Biotechnology
https://www.adctherapeutics.com
NYSE
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relap...
0001771910
CH0499880968
H0036K147
Biopole
41 21 653 02 00
CH
273
May 18, 2020
0001771910
NYSE
Biotechnology
Healthcare
H0036K147
CH0499880968
CH
4.49
1.76
819.94k
370.56M
-
0.36-6.04
-0.06
-
-
-
-
-1.53
-
https://www.adctherapeutics.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.